Antibody Information
General Information of This Antibody (ID: ANTI0MBTTD)
| Antibody Name | A humanized anti-B7-H4 IgG1k mAb |
|||||
|---|---|---|---|---|---|---|
| Antigen Name | B7-H4 |
Antigen Info | ||||
| Click to Show/Hide the Sequence Information of This Antibody | ||||||
Each Antibody-drug Conjugate Related to This Antibody
Full Information of The Activity Data of The ADC(s) Related to This Antibody
LNCB74 [Phase 1]
Identified from the Human Clinical Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Patients Enrolled |
Inclusion: Adults (≥18) with advanced/metastatic solid tumors (RECIST 1.1-measurable), ECOG 0-1, life expectancy ≥12 weeks, adequate organ function, willingness for biopsies, and contraception compliance. Exclusion: Prior MMAE-ADC therapy, platinum-refractory disease, active CNS metastases, Grade≥2 neuropathy/corneal disease, uncontrolled infections (HIV/HBV/HCV), recent anticancer therapies (chemotherapy within 2 weeks, antibodies within 4 weeks, radiotherapy within 2-4 weeks), immunosuppression, or significant comorbidities (cardiovascular, interstitial lung disease, bowel obstruction). Pregnancy, breastfeeding, or unresolved toxicities (>Grade 1) also exclude participation.
Click to Show/Hide
|
||||
| Administration Dosage |
LNCB74 is an antibody drug conjugate being evaluated as a potential treatment for participants with advanced solid tumors. Participants will receive LNCB74 into the vein (IV; intravenously) in 21-day dosing cycles. Participants will continue treatment in the absence of unacceptable toxicities and unequivocal disease progression.
|
||||
| Related Clinical Trial | |||||
| NCT Number | NCT06774963 | Clinical Status | PHASE1 | ||
| Clinical Description |
A Phase 1, Open-label, Dose Escalation and Dose Expansion Study for LNCB74, a B7-H4 Targeted Antibody Drug Conjugate, as Monotherapy in Participants With Advanced Solid Tumors
|
||||
| Primary Endpoint |
The study aims to evaluate the safety and tolerability of LNCB74 over 24 months, assessing incidence of AEs, SAEs, DLTs, discontinuations, and deaths per NCI CTCAE v5.0. Additionally, it seeks to determine the RP2D (based on MTD, MAD, and cumulative safety/PK data) and define the maximum tolerated/feasible dose.
|
||||
| Other Endpoint |
Efficacy measures include ORR, DOR, DCR, and PFS at 6/24 months (per RECIST 1.1), alongside correlations between B7-H4 expression (via central IHC) and clinical outcomes (ORR, DOR, DCR, PFS). Pharmacokinetics (Tmax, AUC, T1/2, Cmax) are evaluated across multiple cycles (Days 1-15, Cycles 1-9). Immunogenicity (anti-drug antibodies) is monitored for 24 months.
Click to Show/Hide
|
||||